MedTrace Logo

Antiphospholipid Antibodies and Fetal Growth Restriction

NCT01538134 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2015-01-05

No results posted yet for this study

Summary

The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of fetal growth restriction (diagnosed postpartum), but this was done without solid evidence of a relation between the two or using the most common form of fetal growth restriction diagnosis (ultrasound). Our study will try to add information to this particular point.

Conditions

  • Fetal Growth Restriction
  • Antiphospholipid Syndrome

Sponsors & Collaborators

  • Saint Thomas Hospital, Panama

    lead OTHER

Principal Investigators

  • Osvaldo Reyes, MD · Saint Thomas Hospital, Panama

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2016-02-29
Completion
2016-03-31

Countries

  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01538134 on ClinicalTrials.gov